IP Library Granted Patent US 8,663,576
Granted Patent B2
US 8,663,576 · App. 12/952,017 · Granted Mar 4, 2014

Detection of intraamniotic infection

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,663,576
App. No.
12/952,017
Granted
Mar 4, 2014
Kind
B2
Abstract

The present invention concerns the identification of biomarkers and groups or combinations of biomarkers that can be used for non-invasive diagnosis of intra-amniotic infection, and diagnostic assays using such biomarkers.

Claims (16)

1. An immunoassay kit for detecting in a biological sample alpha-fetoprotein (AFP), interleukin-6(IL-6), and IGF binding protein-1(IGFBP-1), the kit comprising (a) a container containing antibodies and reagents for the detection of AFP, IL-6 and IGFBP-1 and (b) instructions for using said antibodies and reagents for the diagnosis of intra-amniotic infection in a pregnant female mammalian subject.

2. The kit of claim 1 , wherein the antibodies and reagents comprise a capture antibody and a detector antibody.

3. The kit of claim 2 , wherein the capture antibody and detector antibody are monoclonal antibodies.

4. The kit of claim 2 , wherein the capture antibody and detector antibody are polyclonal antibodies.

5. The kit of claim 2 , wherein the capture antibody and detector antibody are either monoclonal or polyclonal antibodies.

6. The kit of claim 1 , further comprising a lateral flow device, such as an immunochromatographic strip (ICS) tests.

7. The kit of claim 1 , wherein the antibodies comprise monoclonal antibodies having binding specificity for AFP, IL-6 and IGFBP-1, and wherein the kit further comprises an anti-antibody immunoglobulin.

8. The kit of claim 7 , wherein the monoclonal antibodies and the anti-antibody immunoglobulin are contained in separate containers.

9. The kit of claim 8 , wherein the monoclonal antibodies and the anti-antibody immunoglobulin are provided in an amount of about 0.001 mg to about 100 grams.

10. The kit of claim 8 , wherein the monoclonal antibodies and the anti-antibody immunoglobulin are provided in an amount of about 0.01 mg to about 1 gram.

11. The kit of claim 1 , wherein the anti-antibody immunoglobulin is selected from the group consisting of a polyclonal immunoglobulin, protein A and protein G, or functional fragments thereof.

12. The kit of claim 11 , wherein the anti-antibody immunoglobulin is labeled.

13. The kit of claim 1 , further comprising agents for reducing background interference in a test or agents for increasing signal.

14. The kit of claim 1 , further comprising software and algorithms for combining and interpolating marker values to produce a prediction of clinical outcome of interest.

15. The kit of claim 1 , further comprising an apparatus for conducting a test.

16. The kit of claim 1 , wherein all antibodies and reagents are provided in a single container along with a sheet of printed instructions for carrying out the test.

Assignments (6)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →